drugset / Trial / NCT00251186
First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly Patients
Phase 2
Terminated
18 enrolled
University of Medicine and Dentistry of New Jersey
Bristol-Myers Squibb · collabRutgers Cancer Institute of New Jersey · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase II clinical trial measuring the effectiveness of the combination of Capecitabine and cetuximab for first line treatment of colorectal cancer in elderly patients and/or those with multiple comorbidities unable to receive standard chemotherapy. This study will be open approximately 2-3 years. Approximately 36 patients will be enrolled on this study. The study will begin enrolling at The Cancer Institute of New Jersey, with 17 patients in the first group. If more than 4 responses are noted, the accrual will continue to 36 patients throughout CINJOG.
Timeline
- Start
- 2006-04
- Primary completion
- 2006-04
- Completion
- 2006-04
Outcome
Outcome not reported
Stopped (Business): “Funding unavailable”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |